T1	Claim 1236 1532	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
T2	Premise 1057 1235	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
T3	Premise 946 1056	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
T4	Premise 663 945	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
R1	Support Arg1:T2 Arg2:T1	
R2	Support Arg1:T3 Arg2:T1	
R3	Support Arg1:T4 Arg2:T1	
